List of Excipients in Branded Drug DALBAVANCIN

Generic Drugs Containing DALBAVANCIN

Company	Ingredient	NDC	Excipient
Teva Pharmaceuticals Inc	dalbavancin	0480-3325	HYDROCHLORIC ACID
Teva Pharmaceuticals Inc	dalbavancin	0480-3325	LACTOSE MONOHYDRATE
Teva Pharmaceuticals Inc	dalbavancin	0480-3325	MANNITOL
Teva Pharmaceuticals Inc	dalbavancin	0480-3325	SODIUM HYDROXIDE
Meitheal Pharmaceuticals Inc	dalbavancin	71288-034	LACTOSE MONOHYDRATE
Meitheal Pharmaceuticals Inc	dalbavancin	71288-034	MANNITOL
BE Pharmaceuticals Inc	dalbavancin	71839-144	LACTOSE MONOHYDRATE

What are the Most Frequently-Used Excipients in DALBAVANCIN?

# Of NDCs	Excipient
1	HYDROCHLORIC ACID
4	LACTOSE MONOHYDRATE
4	MANNITOL
1	SODIUM HYDROXIDE

Dalbavancin Excipient Strategy and Commercial Opportunities

Last updated: August 17, 2026

Dalbavancin is a long-acting lipoglycopeptide antibiotic with an excipient-light injectable product profile. The commercial opportunity is concentrated in formulation upgrades rather than expansion of the existing vial composition. The strongest opportunities are ready-to-use presentations, lower-volume administration, improved reconstitution, pediatric and outpatient delivery, and differentiated stability profiles.

The current product is an intravenous powder for concentrate containing dalbavancin, mannitol, lactose monohydrate, and pH-adjusting hydrochloric acid. The U.S. formulation is diluted only in 5% dextrose, which creates an avoidable administration constraint for hospitals and outpatient infusion providers.[1] A formulation that tolerates normal saline, reduces preparation steps, or eliminates pharmacy compounding could support premium pricing and switching.

What is dalbavancin and how is it administered?

Dalbavancin is a semisynthetic lipoglycopeptide antibacterial agent related to the glycopeptide class. The U.S. product, DALVANCE, is approved for acute bacterial skin and skin structure infections caused by susceptible Gram-positive organisms, including methicillin-susceptible and methicillin-resistant Staphylococcus aureus and selected streptococci.[1]

The approved adult regimens are:

Regimen	Dose	Administration
Two-dose regimen	1,000 mg on Day 1, followed by 500 mg on Day 8	Intravenous infusion over 30 minutes
Single-dose regimen	1,500 mg	Intravenous infusion over 30 minutes

Each 500 mg vial must be reconstituted with sterile water and then further diluted in 5% dextrose injection. The product should not be mixed with saline because dalbavancin may precipitate in the presence of sodium chloride.[1]

The long terminal half-life, approximately 14 days, permits single-dose or two-dose treatment. That pharmacokinetic profile is the primary commercial asset. It reduces dependence on central venous access, daily infusion, inpatient care, and outpatient adherence.[2]

What excipients are used in the current dalbavancin formulation?

The commercial powder formulation uses a limited excipient system:

Component	Functional role
Mannitol	Bulking agent and lyoprotectant for the freeze-dried cake
Lactose monohydrate	Bulking agent and stabilizer
Hydrochloric acid	pH adjustment
Sterile water for reconstitution	Reconstitution vehicle
5% dextrose injection	Required final dilution vehicle

The formulation is lyophilized because dalbavancin is a complex, high-molecular-weight lipoglycopeptide with stability and solubility constraints. The excipient system must preserve molecular integrity during freezing, primary drying, secondary drying, storage, reconstitution, and infusion.

Lactose has regulatory and commercial implications. It may require labeling attention for patients with severe lactose intolerance or specific excipient sensitivities. Mannitol can affect osmolarity and contributes to the physical properties of the lyophilized cake and reconstituted solution.

The existing composition is commercially functional but not optimized for operational simplicity. It requires:

1. Vial reconstitution.
2. Transfer into a compatible infusion bag.
3. Dilution in 5% dextrose.
4. A 30-minute intravenous infusion.

That workflow creates an opening for excipient and device innovation.

What formulation patents could protect dalbavancin products?

Potentially protectable formulation categories include:

• Stabilized dalbavancin lyophilizates.
• Excipient systems that improve cake structure or reconstitution time.
• Ready-to-use liquid formulations.
• Saline-compatible formulations.
• High-concentration formulations that reduce infusion volume.
• Subcutaneous or intramuscular depot formulations.
• Premixed infusion bags.
• Dual-chamber vial or bag systems.
• Formulations with extended refrigerated or room-temperature stability.
• Low-endotoxin and low-particulate compositions.
• Pediatric-dose presentations.
• Formulations that reduce aggregation, adsorption, or precipitation.

A reformulation patent would need a meaningful technical distinction over the approved mannitol-lactose system and earlier dalbavancin development work. A broad claim covering dalbavancin with a conventional sugar or polyol would face substantial prior-art risk. Stronger claims would likely require measurable performance limits, such as:

• Defined purity after storage.
• Reduced aggregate formation.
• Specified reconstitution time.
• Stability in saline.
• A concentration range that avoids precipitation.
• Reduced infusion volume.
• A defined particle-size or subvisible-particle profile.
• Improved stability after reconstitution.

The commercial value of formulation patents would depend on whether they block a practical alternative or merely cover a narrow laboratory composition. Claims tied to a specific delivery format, such as a ready-to-use bag or dual-chamber system, may have greater commercial leverage than claims limited to excipient identity.

When does dalbavancin lose exclusivity?

Dalbavancin’s original composition-of-matter protection is no longer the principal barrier to competition in the United States. The commercial protection question now turns on regulatory exclusivity, listed patents, formulation patents, method-of-use claims, and the ability of a generic or follow-on manufacturer to develop a pharmaceutically acceptable injectable product.

DALVANCE received U.S. approval in May 2014.[3] The product had five years of new chemical entity exclusivity, subject to statutory adjustment and pediatric provisions. That period has expired.

The key practical exposure is therefore:

Protection category	Current commercial relevance
New chemical entity exclusivity	Expired
Core molecule protection	Expected to be expired or commercially weak
Formulation patents	Potentially relevant if unexpired and listed
Method-of-use patents	Relevant only if claims cover the approved indication or dosing method
Pediatric exclusivity	May have extended selected listed patents, if applicable
Regulatory exclusivity	No longer the principal barrier for the original approval
Injectable manufacturing know-how	Potentially important even where patent protection is limited

Patent expiration should be assessed from the current Orange Book, USPTO records, and litigation filings before any launch decision. The relevant competitor may not need to duplicate the exact commercial excipient composition. An abbreviated new drug application applicant could attempt to use a different excipient system if it demonstrates pharmaceutical equivalence, bioequivalence, product quality, and injectable safety.

What is the Orange Book status of dalbavancin?

DALVANCE is an FDA-approved prescription product, and its listed patent and exclusivity status should be reviewed in the current FDA Orange Book rather than inferred from the original approval date.[4]

The Orange Book analysis should address:

• Whether DALVANCE has active listed patents.
• Whether any patent claims the drug substance, formulation, or method of use.
• Whether a future ANDA applicant must submit a Paragraph IV certification.
• Whether a Paragraph IV notice could trigger a 30-month stay.
• Whether the listed patents expire before or after the likely generic review date.
• Whether the FDA has accepted a product-specific guidance position for dalbavancin.

A Paragraph IV challenge would be commercially credible if the challenger can argue that the listed claim is invalid, unenforceable, or not infringed. Formulation claims are often vulnerable when the claimed excipients perform predictable functions and the prior art discloses similar lyophilized antibiotic compositions. A claim directed to saline compatibility or an unusual stability result may be more defensible if the result is unexpected and supported by reproducible data.

Are there Paragraph IV challenges or generic competitors for dalbavancin?

The generic risk is technically more complex than for a conventional small-molecule tablet but lower than for a biologic. Dalbavancin is a chemically defined antibiotic, so it is generally more suitable for an ANDA pathway than a monoclonal antibody. The product is still difficult to copy because it is:

• A complex lipoglycopeptide.
• Administered intravenously.
• Supplied as a sterile lyophilized product.
• Sensitive to formulation and dilution conditions.
• Subject to stringent impurity, aggregate, endotoxin, and particulate controls.
• Used at a high dose with a narrow practical tolerance for precipitation or infusion defects.

An ANDA applicant would likely target the existing 500 mg vial first. The most probable generic product would use a different or modified lyophilization system, provided it meets FDA quality and equivalence requirements.

Generic entry scenarios include:

Scenario	Commercial effect
First ANDA approval without launch	Limited immediate erosion; may create settlement leverage
One generic entrant	Hospital price pressure and contracting concessions
Multiple injectable entrants	Accelerated price erosion and formulary substitution
Authorized generic	Slower third-party uptake but lower net price
Reformulated branded product	Potential lifecycle extension if clinically and operationally superior
Compounded or off-label supply	Quality and regulatory concerns; limited substitution value

Biosimilar risk is not the primary issue. Dalbavancin is not a biologic requiring a biosimilar pathway under the Public Health Service Act. The relevant competitors are generic injectable products, branded reformulations, alternative long-acting antibiotics, and off-label use of other agents.

What excipient changes could create commercial value?

Saline-compatible dalbavancin

The highest-value excipient objective is likely saline compatibility. Hospitals commonly use 0.9% sodium chloride as an infusion vehicle. Requiring 5% dextrose adds inventory, preparation, and error-management requirements.

A saline-compatible formulation could:

• Expand infusion-site compatibility.
• Reduce pharmacy exceptions.
• Simplify nursing workflows.
• Improve use in emergency departments and ambulatory centers.
• Reduce risk of improper dilution.
• Support premixed or ready-to-administer products.

The formulation would need to control ionic strength, pH, aggregation, and precipitation. A claim covering saline compatibility should define the concentration, storage period, temperature, and acceptable particulate and potency limits.

Ready-to-use liquid product

A stable liquid dalbavancin product could eliminate reconstitution and reduce pharmacy handling. The main barriers are long-term stability, concentration, viscosity, container adsorption, oxidation, and microbial control.

Possible presentations include:

• A prefilled infusion bag.
• A vial containing a concentrated solution.
• A ready-to-use bottle.
• A dual-chamber container separating drug and diluent until use.

A liquid product would carry higher cold-chain and container-closure requirements than the current powder. Its commercial value would depend on whether the operational benefit exceeds increased manufacturing and distribution costs.

Higher-concentration formulation

The approved product requires a 30-minute infusion. A higher-concentration formulation could reduce infusion volume and potentially shorten administration time, subject to clinical validation.

Key technical risks include:

• Precipitation at high concentration.
• Increased viscosity.
• Local tolerability if nonintravenous delivery is pursued.
• Greater sensitivity to pH and ionic strength.
• Higher particulate burden.
• More difficult sterilizing filtration.

Improved lyophilized cake

A redesigned lyophilized product could reduce reconstitution time and improve handling without changing the clinical dose. Candidate excipient strategies include alternative polyols, disaccharides, amino acids, buffering agents, and surfactants.

The strongest commercial formulation would produce a measurable operational improvement, such as reconstitution in less than one minute, reduced foaming, lower particulate formation, or stability after partial preparation.

Pediatric formulation

Dalbavancin has pediatric use potential because a single or infrequent infusion can reduce prolonged venous access. A pediatric product could use:

• Lower-dose vials.
• More flexible concentration ranges.
• Reduced dead volume.
• A formulation with a smaller final infusion volume.
• A ready-to-use liquid suitable for weight-based dosing.

Pediatric development could support regulatory exclusivity if a sponsor completes an FDA-requested study and receives the applicable six-month pediatric extension. The commercial segment is smaller than adult acute bacterial skin infection, but the clinical workflow advantage may be substantial in children requiring prolonged Gram-positive coverage.[1]

How does dalbavancin compare with other long-acting antibiotics?

Product	Active ingredient	Typical administration	Excipient and delivery opportunity
DALVANCE	Dalbavancin	Single dose or two IV doses	Saline compatibility, ready-to-use presentation, pediatric dosing
ORBACTIV	Oritavancin	Single IV dose	Infusion preparation and compatibility improvements
VABOMERE or conventional agents	Other antibacterials	More frequent dosing	Less direct competition on dosing frequency
Long-acting outpatient regimens	Various	Daily or intermittent administration	Compete on total treatment cost and site-of-care convenience

Dalbavancin’s main differentiation is prolonged exposure. Oritavancin also offers single-dose intravenous treatment, so formulation improvements must address preparation time, infusion logistics, compatibility, and total care cost rather than dosing frequency alone.[5]

A dalbavancin reformulation can compete effectively when it makes the same pharmacologic benefit easier to deploy. A lower acquisition price alone may not protect the product from generic substitution.

What commercial opportunities exist for dalbavancin excipients and delivery systems?

Hospital and outpatient infusion channels

A saline-compatible, low-preparation product could target:

• Emergency departments.
• Hospital discharge programs.
• Outpatient parenteral antimicrobial therapy services.
• Ambulatory infusion centers.
• Skilled nursing facilities.
• Rural hospitals.
• Correctional health systems.
• Home-infusion providers.

The economic case is strongest where dalbavancin prevents admission or avoids placement of a peripherally inserted central catheter. Published economic analyses have identified potential savings from reduced hospitalization and outpatient treatment requirements, although the result depends on acquisition price, patient selection, and local care pathways.[6]

Infectious disease and substance-use populations

Dalbavancin is used off label in some settings requiring prolonged Gram-positive treatment, including selected patients with barriers to conventional outpatient intravenous therapy. These uses may include osteomyelitis, endocarditis, and bloodstream infection, although evidence and regulatory status vary by indication.

A formulation that simplifies administration may have value in patients with:

• Unstable housing.
• Limited access to daily infusion.
• High risk of line misuse.
• Poor adherence to multidose therapy.
• Difficulty maintaining outpatient follow-up.

A sponsor should distinguish approved-label commercial claims from off-label utilization. Method-of-use patent claims directed to unapproved indications may face written-description, enablement, obviousness, and regulatory-enforcement risks.

Contract manufacturing and excipient suppliers

Commercial opportunities exist for suppliers with capabilities in:

• Sterile lyophilization.
• High-potency antibiotic handling.
• Low-particulate injectable manufacturing.
• Container-closure compatibility.
• Freeze-drying cycle development.
• Dual-chamber packaging.
• Premixed infusion manufacturing.
• Stability-indicating analytical methods.

The manufacturing barrier may be more important than the excipient itself. Dalbavancin production requires control of complex impurities and a robust sterile fill-finish process. A supplier with a validated cycle and scalable process can create licensing value even where the composition claims are narrow.

What patent and regulatory strategy best protects a dalbavancin reformulation?

A durable strategy would use multiple claim layers:

1. Composition claims covering the excipient range and pH.
2. Lyophilization-process claims covering the drying cycle and residual moisture.
3. Stability claims covering potency, aggregates, and particulates.
4. Dilution claims covering saline or other infusion vehicles.
5. Container claims covering premixed or dual-chamber systems.
6. Administration claims covering a reduced infusion time or lower volume.
7. Pediatric or weight-based dosing claims where supported by clinical data.
8. Manufacturing claims covering impurity control or yield improvement.

The regulatory strategy should align with the product type:

Product change	Likely regulatory path
Same drug, different excipient or vial	505(b)(2) or other FDA pathway, depending on differences
Ready-to-use formulation	505(b)(2) likely relevant if relying on existing clinical data
New route of administration	New clinical and regulatory package
Generic equivalent	ANDA
New indication	Supplemental NDA or 505(b)(2), supported by clinical evidence
Pediatric dosing expansion	Supplemental filing and possible pediatric exclusivity

FDA has approved dalbavancin for acute bacterial skin and skin structure infections, not for every use supported by clinical practice or observational evidence.[1] Any commercial plan relying on osteomyelitis, endocarditis, or bloodstream infection would require a separate evidence and promotional analysis.

How strong is the dalbavancin patent estate?

The original molecule is less strategically important than incremental protection. A new entrant would face a moderate technical barrier but a potentially manageable patent barrier if no strong active formulation or method-of-use claims remain.

Patent strength is highest where claims:

• Cover a required commercial feature.
• Have narrow but reproducible technical parameters.
• Show unexpected stability or compatibility.
• Are supported by comparative data.
• Cover the container and formulation together.
• Are difficult to design around without losing commercial utility.

Patent strength is weaker where claims:

• Cover conventional mannitol or lactose use without unexpected results.
• Define broad excipient classes.
• Rely on routine lyophilization parameters.
• Claim unapproved uses without robust clinical support.
• Can be avoided by changing the dilution vehicle or vial strength.

The most defensible lifecycle product would combine a practical administration advantage with a patent family that covers composition, process, and presentation.

What litigation and settlement issues affect dalbavancin?

A future Paragraph IV dispute would likely focus on:

• Validity of formulation claims.
• Obviousness of the excipient combination.
• Infringement by an alternative lyophilized cake.
• Whether a method-of-use claim covers the ANDA label.
• Whether the generic applicant’s proposed label induces infringement.
• Patent listing accuracy in the Orange Book.
• The scope of any 30-month stay.

A settlement could include a licensed entry date, authorized generic provisions, supply arrangements, or restrictions tied to specific indications. The commercial value of settlement terms would depend on the number of potential ANDA applicants and the economic importance of hospital contracts.

No settlement should be valued solely by the nominal launch date. The analysis should include authorized-generic exposure, contract price reductions, at-risk launch probability, and the possibility that a generic enters with a noninfringing formulation.

What revenue exposure exists for dalbavancin?

Revenue exposure is driven by treatment setting rather than prescription volume alone. Dalbavancin has a high per-course acquisition cost relative to many conventional antibiotics, but it can reduce total cost where it substitutes for inpatient days, daily infusions, or central-line management.

Commercial metrics should include:

• Net sales by geography.
• Average price per 500 mg vial.
• Average vials per course.
• Single-dose versus two-dose utilization.
• Hospital versus outpatient mix.
• Contracting discounts.
• Percentage of use in approved versus off-label settings.
• Cost avoided per treated patient.
• Generic price erosion under one-, two-, and multiple-entrant scenarios.

The highest-value customers are likely to be institutions that can convert hospital-based treatment into outpatient administration. A ready-to-use or saline-compatible product could capture additional value through pharmacy labor savings and reduced preparation failures, not only through antibiotic efficacy.

Key Takeaways

• Dalbavancin’s current product uses a mannitol-lactose lyophilized formulation and requires dilution in 5% dextrose.
• Saline incompatibility is the clearest excipient-related commercial weakness.
• Ready-to-use liquid, premixed, dual-chamber, and higher-concentration products are the main lifecycle opportunities.
• The original regulatory exclusivity period has expired; future protection depends on active patents, formulation claims, manufacturing know-how, and clinical differentiation.
• Generic competition is more likely to arrive through an ANDA than a biosimilar pathway.
• A strong reformulation patent should include measurable stability, compatibility, reconstitution, or administration advantages.
• Pediatric and outpatient-delivery products could extend the commercial franchise if supported by regulatory evidence.
• The economic case depends on avoided hospital days, reduced line care, and lower treatment burden, not only on vial price.
• Manufacturing capability in sterile lyophilization and complex injectable quality control may be a larger barrier than excipient sourcing.

FAQs

Can dalbavancin be diluted in normal saline?

The U.S. DALVANCE label directs dilution in 5% dextrose injection and warns against saline because precipitation may occur.[1]

Could a new dalbavancin product use trehalose instead of lactose?

Potentially, but the sponsor would need to demonstrate acceptable potency, impurity profile, aggregation control, cake structure, reconstitution, sterility, and clinical suitability. Trehalose could support a differentiated formulation claim only if the resulting product has patentable and commercially meaningful performance.

Is a ready-to-use dalbavancin infusion likely to receive generic approval?

A ready-to-use product would generally be a product-design and regulatory-pathway question. If it differs materially from the reference product, a 505(b)(2) approach may be more appropriate than an ANDA, while a generic vial would more naturally target the ANDA pathway.

Does dalbavancin have biosimilar competition?

No. Dalbavancin is a chemically defined antibiotic, not a biologic subject to the biosimilar framework. Competition would primarily come from generic injectable products and alternative long-acting antibiotics.

What is the most valuable dalbavancin formulation patent?

A patent covering a stable, saline-compatible, ready-to-administer formulation with reduced preparation time would likely have greater commercial value than a patent covering a conventional excipient substitution without a demonstrated operational benefit.

References

1. U.S. Food and Drug Administration. (2023). DALVANCE (dalbavancin hydrochloride) for injection: Prescribing information. Melinta Therapeutics, LLC.

2. Dunne, M. W., Puttagunta, S., Giacobbe, R., et al. (2015). A randomized clinical trial of single-dose versus weekly dalbavancin for the treatment of acute bacterial skin and skin structure infection. Clinical Infectious Diseases, 62(5), 545-551.

3. U.S. Food and Drug Administration. (2014). FDA approves Dalvance to treat acute bacterial skin infections. FDA.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

5. Corey, G. R., Kabler, H., Mehra, P., et al. (2014). Single-dose oritavancin in the treatment of acute bacterial skin infections. New England Journal of Medicine, 370(23), 2180-2190.

6. Kaye, K. S., et al. (2016). Economic and clinical outcomes associated with dalbavancin treatment of acute bacterial skin and skin structure infections. Clinical Infectious Diseases.